Financial Data and Key Metrics Changes - Revenue for the year increased by 82% to $6,000,000,000, driven by market share growth and the Sigma wholesale business [6][10] - Normalized EBIT rose by 41% to $835,000,000, with pro forma EBIT at $903,400,000 [6][10] - Normalized net profit after tax increased by 40% to $579,000,000, with a strong balance sheet showing net debt of $752,000,000 [6][11] Business Line Data and Key Metrics Changes - Chemist Warehouse retail network sales reached $10,000,000,000, up 14% for the year, with 35 new stores added [3][4] - Own brand portfolio grew by over 20%, contributing significantly to the growth strategy [4][30] - Combined distribution center volumes increased by 29%, leading to a reduction in cost per unit by $0.11 [4][11] Market Data and Key Metrics Changes - The Chemist Warehouse Australian store network delivered 11.3% like-for-like sales growth [17] - International expansion included 16 new stores opened offshore, with a total of 77 stores across New Zealand, Ireland, and Dubai [28] - The company anticipates continued growth in the international markets, particularly in New Zealand [28][29] Company Strategy and Development Direction - The company focuses on four key growth pillars: domestic growth, international expansion, product differentiation, and improved efficiencies [23][24] - Domestic growth aims to expand market leadership and pharmacy network in underpenetrated locations [25] - International expansion is seen as an emerging growth engine, with a focus on profitable growth in existing markets [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute plans effectively, with positive momentum continuing into FY 2026 [34][35] - The merger is expected to provide significant synergies, with an upgraded target of $100,000,000 per annum [5][48] - Management noted that the health and beauty space remains competitive, but the company continues to gain market share [66] Other Important Information - The company declared a final dividend of $0.13 per share, fully franked, in line with its stated payout ratio [6][21] - The balance sheet remains strong, with a conservative leverage ratio of 0.85x [11][20] Q&A Session Summary Question: Discussion on Wagner's product profit increment into 2026 - Management indicated that while there was a benefit in 2025, full-year benefits from Wagner are expected in 2026 as the product range expands [37] Question: Margin drivers and synergy achievement - Management stated that margin enhancement will come from a mix of own label products, operating leverage, and growth [38] Question: Cost inflation and operating leverage - Management explained that operating leverage will be driven by existing capacity in distribution centers, with some inflation expected [44] Question: Synergy upgrade from $60 million to $100 million - The upgrade was driven by detailed data analysis post-merger, identifying multiple areas for synergy beyond just supply terms [48] Question: Addressing under-penetration in certain markets - Management noted that regulatory challenges exist, but they have successfully worked with regulators to gain approvals for new stores [52] Question: Expected D&A and CapEx for FY 2026 - Management expects D&A to remain consistent, with CapEx also expected to be stable unless compelling investment opportunities arise [56][57] Question: Impact of establishing a distribution center in Ireland - Management believes the new DC will positively impact profitability and support growth in the Irish market [60][62] Question: Competitive dynamics in health and beauty products - Management acknowledged competition but emphasized their competitive pricing and product range as advantages [66] Question: Uptake of GLP-1 products - Management confirmed a material uptake in GLP-1 products, expecting continued growth without a slowdown [68]